Mark May joins Sonoma Biotherapeutics with over 10 years of accounting and finance experience with a demonstrated history of successfully implementing financial processes and systems.
May was most recently at Sangamo Therapeutics where he was responsible for various accounting and finance functions, including accounting, audit, forecasting, treasury and accounts payable operations. Prior to Sangamo, he was at Medivation and played an integral role after the company was acquired by Pfizer. Earlier in his career he held a role in public accounting with Deloitte.
May earned a BS degree in Accounting from Santa Clara University.